At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 210 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Placebo for Obesity and 2 related conditions. Completed, enrolled 210 participants across 29 sites.
Detailed Summary
This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight. The main purpose is to learn more about how tirzepatide affects body weight.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Overweight, Metabolism and Nutrition Disorder
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartSep 2021
Primary CompletionDec 2022
TodayJul 2026
First PostedAug 27, 2021
Enrollment StartSep 1, 2021
Primary CompletionDec 27, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.8 years ago
Interventions
Tirzepatidedrug
Administered SC
Placebodrug
Administered SC